




March 2012



Novel TB regimen development

Our R&D Partners			
AZ	AstraZeneca	NITD	Novartis Institute for Tropical Diseases
Bayer	Bayer Healthcare AG	Novartis	Novartis Pharmaceutical
BTTTRI	Beijing Tuberculosis and Thoracic Tumor Research Institute	NYMC	New York Medical College
GSK	GlaxoSmithKline	Tibotec	Johnson & Johnson / Tibotec
IMCAS	Institute of Microbiology, Chinese Academy of Sciences	U. of Auck	University of Auckland
IMM	Institute of Materia Medica	U. Penn	University of Pennsylvania School of Medicine
JHU	Johns Hopkins University	Yonsei	Yonsei University